AllSci News
Weill Cornell Medical College receives USD 3.6m NIH grant for tuberculosis treatment duration research
Weill Cornell Medical College has received a USD 3.6 million NIH Program Project grant to investigate the microbial determinants of tuberculosis treatment...
Cardiff Oncology's onvansertib shows 72% response rate in first-line RAS-mutated mCRC
San Diego-based Cardiff Oncology (Nasdaq: CRDF) reported that onvansertib, an oral PLK1 inhibitor, produced a confirmed objective response rate of 72.2% in...
Cencora to support US distribution of Kite’s approved CAR-T cell therapies
Conshohocken, Pennsylvania-based Cencora (NYSE: COR) and Kite, a Gilead Sciences (Nasdaq: GILD) company, announced a distribution agreement covering two US FDA-approved CAR…
Arcus, BMS collaborate on casdatifan plus pumitamig for advanced renal cell carcinoma
California-based Arcus Biosciences (NYSE: RCUS) and Bristol Myers Squibb (BMS; NYSE: BMY) announced a clinical trial collaboration and supply agreement to evaluate…
Eli Lilly commits USD 1.9b to access Ascidian's RNA exon editing platform for kidney diseases
Eli Lilly (NYSE: LLY) has committed up to USD 1.9 billion to access Boston-based Ascidian Therapeutics' RNA exon editing platform for inherited kidney...
IDefine and UT Southwestern collaborate on EHMT1 gene therapy for Kleefstra syndrome
IDefine – The Kleefstra Syndrome Foundation, an Atlanta-based nonprofit patient advocacy organization, and UT Southwestern Medical Center announced a two-year pre-clinical research…
FDA accepts Roche's giredestrant NDA for early-stage ER-positive breast cancer adjuvant treatment
Roche (SIX: RO, ROP; OTCQX: RHHBY) has submitted a New Drug Application (NDA) to the US FDA for giredestrant, an investigational oral selective estrogen...
Contraline closes USD 92.5m Series B for male contraceptive gel development
Charlottesville, Virginia-based Contraline, Inc., a clinical-stage biopharmaceutical company developing male contraceptives, has closed a USD 92.5 million...
Replimune to resubmit BLA for oncolytic IO therapy Rp1 in melanoma after FDA alignment
Woburn, Massachusetts-based Replimune Group (Nasdaq: REPL) has announced plans to resubmit a Biologics License Application (BLA) to the US FDA for Rp1...
Legend Bio posts early data for CD19/CD20 in vivo CAR-T showing 100% response rate in NHL
Legend Biotech (Nasdaq: LEGN) reported a 100% objective response rate in six evaluable patients treated at the higher dose level of LB2501, its...
Travere picks up BTKi civorebrutinib from Everest Medicines in USD 1.14b deal
Travere Therapeutics (Nasdaq: TVTX) has committed USD 112.5 million upfront to license civorebrutinib, a covalent reversible BTK inhibitor developed by...
Ideaya and Roche to try out PRMT5 + pan-RAS inhibition against pancreatic cancer
South San Francisco-based Ideaya Biosciences (Nasdaq: IDYA) has entered a clinical collaboration with Roche to test whether combining an MTA-cooperative...
Merakris’ MTX-001 amniotic fluid biologic receives FDA Fast Track designation for venous leg ulcers
North Carolina-based Merakris Therapeutics received US FDA Fast Track designation status for MTX-001, its lead biologic candidate, for the treatment of chronic,…
Cumberland's ifetroban shows ability to block tumor metastasis in Phase IIa trial
Nashville-based Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) reported that ifetroban, its thromboxane A2 receptor antagonist, met the primary safety...
Lysoway Therapeutics secures USD 3.4m Michael J. Fox Foundation grant for TMEM175 Parkinson's program
Lysoway Therapeutics, a Cambridge, Massachusetts-based biopharmaceutical company focused on lysosomal ion channel modulators, has received approximately USD...
The AllSci Brief
Systematic R&D and deal news. Daily.